Aligos Therapeutics, Inc. announced that effective May 21, 2024, Jack Nielsen, a member of the board of directors., resigned from the Board. Following Mr. Nielsen?s departure, a vacancy was created on the Company?s Audit Committee, resulting in there being two members of the Audit Committee . Nasdaq Stock Market LLC Listing Rule 5605(c)(2)(A) requires that the Company have an Audit Committee composed of three members that satisfy certain criteria for service on the committee.

Mr. Nielsen?s resignation was for personal reasons.